IMPORTANCE: The World Health Organization recommends at least 3 annual mass drug administrations (MDAs) of azithromycin in places where the prevalence of follicular trachoma (FT) is greater than 10%. However, stopping MDA prior to 3 rounds, if monitoring indicates an absence of infection with Chlamydia trachomatis even if FT persists, may be more cost-effective. OBJECTIVE: To determine the prevalence of infection in communities randomized to 3 rounds of annual MDAs with azithromycin compared with communities randomized to a stopping rule, where MDA could cease if the infection rate was low. DESIGN A 1:1 community randomized trial comparing usual care with a cessation rule. The Partnership for the Rapid Elimination of Trachoma-Ziada Trial was conducted from February 1, 2010, through September 1, 2011. SETTING: Sixteen communities in Tanzania with trachoma prevalence rates between 10% and 20%. PARTICIPANTS: A total of 100 children aged 5 years or younger randomly drawn from each community. Children had to reside in an eligible community, have no ocular condition that prevented trachoma grading or ocular specimen collection, and have a guardian who could provide consent for participation. INTERVENTIONS: Cessation of MDA with azithromycin if the community had no infection in their sample at 6 months or 18 months. MAIN OUTCOME MEASURE: The prevalence of C trachomatis at 18 months. RESULTS: None of the intervention communities met criteria to stop MDA based on the 6-month or 18-month survey; all, as well as the usual care communities, were scheduled for a third MDA round. There was no difference in infection (2.9% vs 4.7%; P = .25) between the usual care and cessation rule communities at 18 months. CONCLUSIONS AND RELEVANCE: In this setting, communities with low (10%-20%) initial prevalence of active trachoma did not have MDA stopped before 3 annual rounds on the basis of monitoring for infection. Infection with C trachomatis in communities with average trachoma rates at 12% to 13% cannot be eliminated before 3 rounds of MDA with azithromycin. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00792922.
RCT Entities:
IMPORTANCE: The World Health Organization recommends at least 3 annual mass drug administrations (MDAs) of azithromycin in places where the prevalence of follicular trachoma (FT) is greater than 10%. However, stopping MDA prior to 3 rounds, if monitoring indicates an absence of infection with Chlamydia trachomatis even if FT persists, may be more cost-effective. OBJECTIVE: To determine the prevalence of infection in communities randomized to 3 rounds of annual MDAs with azithromycin compared with communities randomized to a stopping rule, where MDA could cease if the infection rate was low. DESIGN A 1:1 community randomized trial comparing usual care with a cessation rule. The Partnership for the Rapid Elimination of Trachoma-Ziada Trial was conducted from February 1, 2010, through September 1, 2011. SETTING: Sixteen communities in Tanzania with trachoma prevalence rates between 10% and 20%. PARTICIPANTS: A total of 100 children aged 5 years or younger randomly drawn from each community. Children had to reside in an eligible community, have no ocular condition that prevented trachoma grading or ocular specimen collection, and have a guardian who could provide consent for participation. INTERVENTIONS: Cessation of MDA with azithromycin if the community had no infection in their sample at 6 months or 18 months. MAIN OUTCOME MEASURE: The prevalence of C trachomatis at 18 months. RESULTS: None of the intervention communities met criteria to stop MDA based on the 6-month or 18-month survey; all, as well as the usual care communities, were scheduled for a third MDA round. There was no difference in infection (2.9% vs 4.7%; P = .25) between the usual care and cessation rule communities at 18 months. CONCLUSIONS AND RELEVANCE: In this setting, communities with low (10%-20%) initial prevalence of active trachoma did not have MDA stopped before 3 annual rounds on the basis of monitoring for infection. Infection with C trachomatis in communities with average trachoma rates at 12% to 13% cannot be eliminated before 3 rounds of MDA with azithromycin. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00792922.
Authors: Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West Journal: Ophthalmic Epidemiol Date: 2011-02 Impact factor: 1.648
Authors: Teshome Gebre; Berhan Ayele; Mulat Zerihun; Asrat Genet; Nicole E Stoller; Zhaoxia Zhou; Jenafir I House; Sun N Yu; Kathryn J Ray; Paul M Emerson; Jeremy D Keenan; Travis C Porco; Thomas M Lietman; Bruce D Gaynor Journal: Lancet Date: 2011-12-20 Impact factor: 79.321
Authors: Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey Journal: N Engl J Med Date: 2004-11-04 Impact factor: 91.245
Authors: Aimee Teo Broman; Kenny Shum; Beatriz Munoz; Donald D Duncan; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2006-01 Impact factor: 4.799
Authors: Beatriz Munoz; Dianne Stare; Harran Mkocha; Charlotte Gaydos; Thomas Quinn; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2011-11-11 Impact factor: 4.799
Authors: Elizabeth N Ssemanda; Beatriz Munoz; Emma M Harding-Esch; Tansy Edwards; Harran Mkocha; Robin L Bailey; Ansumana Sillah; Dianne Stare; David C W Mabey; Sheila K West Journal: PLoS Negl Trop Dis Date: 2010-10-05
Authors: Emma M Harding-Esch; Tansy Edwards; Harran Mkocha; Beatriz Munoz; Martin J Holland; Sarah E Burr; Ansumana Sillah; Charlotte A Gaydos; Dianne Stare; David C W Mabey; Robin L Bailey; Sheila K West Journal: PLoS Negl Trop Dis Date: 2010-11-02
Authors: Catherine E Oldenburg; Abdou Amza; Boubacar Kadri; Beido Nassirou; Sun Y Cotter; Nicole E Stoller; Sheila K West; Robin L Bailey; Travis C Porco; Bruce D Gaynor; Jeremy D Keenan; Thomas M Lietman Journal: Am J Trop Med Hyg Date: 2017-12-14 Impact factor: 2.345
Authors: Abdou Amza; Boubacar Kadri; Beido Nassirou; Sun Y Cotter; Nicole E Stoller; Sheila K West; Robin L Bailey; Travis C Porco; Bruce D Gaynor; Jeremy D Keenan; Thomas M Lietman; Catherine E Oldenburg Journal: Br J Ophthalmol Date: 2017-09-11 Impact factor: 4.638
Authors: Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch Journal: Cochrane Database Syst Rev Date: 2019-09-26
Authors: Robert Butcher; Jo Houghton; Tamsyn Derrick; Athumani Ramadhani; Beatriz Herrera; Anna R Last; Patrick A Massae; Matthew J Burton; Martin J Holland; Chrissy H Roberts Journal: J Microbiol Methods Date: 2017-05-06 Impact factor: 2.363
Authors: Robert M R Butcher; Oliver Sokana; Kelvin Jack; Colin K Macleod; Michael E Marks; Eric Kalae; Leslie Sui; Charles Russell; Helena J Tutill; Rachel J Williams; Judith Breuer; Rebecca Willis; Richard T Le Mesurier; David C W Mabey; Anthony W Solomon; Chrissy H Roberts Journal: PLoS Negl Trop Dis Date: 2016-09-07
Authors: Robert Butcher; Oliver Sokana; Kelvin Jack; Leslie Sui; Charles Russell; Anna Last; Diana L Martin; Matthew J Burton; Anthony W Solomon; David C W Mabey; Chrissy H Roberts Journal: Wellcome Open Res Date: 2018-02-22